Initiator Pharma Completes Dosing in Phase 2a Vulvodynia Study
Initiator Pharma said dosing is complete in its Phase 2a study of pudafensine for vulvodynia.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Initiator Pharma Completes Dosing of Final Patient in Phase 2a Vulvodynia Study
Initiator Pharma says the final patient in its Phase 2a study of pudafensine for vulvodynia has completed dosing.